Xelpros®
Latanoprost 0.005% · ophthalmic emulsion
Antiglaucoma
Approved uses
Open-angle glaucoma or ocular hypertension
One drop in the affected eye(s) once daily in the evening; not to exceed once daily.
IOP begins to fall 3 to 4 hours after dosing, peaks at 8 to 12 hours, and lasts at least 24 hours.
Contraindications
Known hypersensitivity to latanoprost or any other ingredient in this product.
0.005% (50 mcg/mL) ophthalmic emulsion, 2.5 mL fill in a 5 mL bottle, package of 1 bottle, multi-pack of 3 bottles
Prostaglandin F2alpha analogue supplied as an isopropyl ester prodrug that corneal esterases hydrolyze to the active acid; it is believed to reduce IOP by increasing aqueous outflow, and studies in animals and man suggest the main mechanism is increased uveoscleral outflow, which class reviews attribute to matrix metalloproteinase remodeling that widens the spaces between ciliary muscle fibers. Onset is 3 to 4 hours after instillation, maximum effect at 8 to 12 hours, and IOP reduction persists at least 24 hours.
Warnings & Precautions
- Iris pigmentation: Pigmentation is expected to increase as long as latanoprost is administered, from increased melanin content in melanocytes rather than more melanocytes. It is likely to be permanent after discontinuation, may not be noticeable for several months to years, and its long-term effects are not known. Typically, brown pigmentation around the pupil spreads toward the periphery; nevi and freckles appear unaffected. Inform patients, and examine regularly those with noticeably increased pigmentation.
- Periorbital pigmentation and eyelash changes: Pigmentation of the periorbital tissue (eyelid) has been reported to be reversible in some patients after discontinuation. Latanoprost may gradually change eyelashes and vellus hair in the treated eye, including increased length, thickness, pigmentation, number of lashes or hairs, and misdirected growth; eyelash changes are usually reversible upon discontinuation.
- Intraocular inflammation: Caution with a history of iritis or uveitis, and generally not for use with active intraocular inflammation, which may be exacerbated.
- Macular edema: Macular edema including cystoid macular edema has been reported with latanoprost products; caution in aphakia, in pseudophakia with a torn posterior lens capsule, and with other known risk factors.
- Herpetic keratitis: Reactivation of herpes simplex keratitis has been reported with latanoprost; caution with a history of it, and avoid in active herpes simplex keratitis, which may be exacerbated.
- Bacterial keratitis: Reported with inadvertently contaminated multiple-dose containers, in most cases in patients with concurrent corneal disease or a disrupted ocular epithelial surface.
- Contact lens use: Remove lenses before instillation and reinsert 15 minutes after.
- Decreased IOP lowering effect: The combined use of two or more prostaglandins or prostaglandin analogs is not recommended. Administration of these products more than once daily may decrease the IOP lowering effect or cause paradoxical elevations in IOP.
- Precipitation: Precipitation occurs in vitro when thimerosal drops are mixed with this emulsion; separate concurrent topical drops by at least 5 minutes.
Common Side Effects
The most common ocular adverse reactions (incidence 5% or more) in 448 patients were eye pain or stinging upon instillation (55%), ocular hyperemia (41%), conjunctival hyperemia (15%), eye discharge (12%), growth of eyelashes (11%), and eyelash thickening (8%). Other ocular adverse reactions reported by 1% or more of patients were ocular itching (5%), reduced visual acuity (4%), dry eye (3%), erythema of eyelid (3%), foreign body sensation (2%), eyelid edema (2%), punctate keratitis (1%), eyelash discoloration (1%), and conjunctival edema (1%). Less than 1% of patients discontinued therapy because of intolerance to the eye pain or stinging or to the ocular hyperemia. Reactions identified during postmarketing use of topical latanoprost products include intraocular inflammation (iritis/uveitis), macular edema, herpes keratitis, asthma, dyspnea, angina, and toxic epidermal necrolysis.
Pregnancy: No adequate and well-controlled studies in pregnant women. IV latanoprost given to pregnant rabbits and rats through organogenesis produced malformations, embryofetal lethality, and spontaneous abortion at clinically relevant doses, with post-implantation loss in rabbits at 1.3 times the maximum recommended human ophthalmic dose and cleft palate in rats at 3.2 times.
Lactation: It is not known whether this drug or its metabolites are excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when XELPROS is administered to a nursing woman. Weigh the benefits of breastfeeding against the mother's clinical need and any potential adverse effects on the breastfed child.
Safety and effectiveness not established in pediatric patients.